Progress in prostate cancer prevention.
Eur J Cancer Prev
; 31(6): 554-557, 2022 11 01.
Article
em En
| MEDLINE
| ID: mdl-35352690
ABSTRACT
After lung, prostate cancer is the second most frequently diagnosed cancer and fourth in cancer-related mortality. The etiology is largely unknown and no clear risk factors have been identified. Primary prevention is therefore challenging. Also, secondary prevention, screening, in large populations is difficult. Germline mutations are implicated in hereditary prostate cancer, accounting for about 10% of screened men. Currently, only prostate-specific antigen test is adopted for early detection but is considered insufficient to further improve prevention and care. In this opinion article, we discuss novel diagnostic biomarkers and imaging tools, along with more promising targeted prostate biopsies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Antígeno Prostático Específico
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
Eur J Cancer Prev
Assunto da revista:
NEOPLASIAS
/
SAUDE PUBLICA
Ano de publicação:
2022
Tipo de documento:
Article